OncoTracker has a total of 41 patents globally, out of which 12 have been granted. Of these 41 patents, more than 78% patents are active. The United States of America is where OncoTracker has filed the maximum number of patents, followed by Europe and Hong Kong (S.A.R.). Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of OncoTracker.
OncoTracker was founded in 2014. OncoTracker is a cancer therapy innovation incubator specializing on the diagnosis and treatment of multiple myeloma, other B-cell malignancies, and related illnesses.
Do read about some of the most popular patents of OncoTracker which have been covered by us in this article and also you can find OncoTracker patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over OncoTracker patent portfolio.
How many patents does OncoTracker have?
OncoTracker has a total of 41 patents globally. These patents belong to 9 unique patent families. Out of 41 patents, 32 patents are active.
How Many Patents did OncoTracker File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | OncoTracker Applications Filed | OncoTracker Patents Granted |
| 2023 | 1 | 2 |
| 2022 | 1 | 3 |
| 2021 | 1 | 4 |
| 2020 | 1 | – |
| 2019 | 5 | 1 |
| 2018 | 8 | 2 |
| 2017 | 8 | – |
| 2016 | 14 | – |
| 2015 | 1 | – |
| 2014 | 1 | – |
How many OncoTracker patents are Alive/Dead?
Worldwide Patents
How Many Patents did OncoTracker File in Different Countries?
Countries in which OncoTracker Filed Patents
| Country | Patent |
| United States Of America | 10 |
| Europe | 5 |
| Hong Kong (S.A.R.) | 4 |
| Singapore | 2 |
| Japan | 2 |
| Brazil | 1 |
| Philippines | 1 |
| Malaysia | 1 |
| Canada | 1 |
| Saudi Arabia | 1 |
| Indonesia | 1 |
| South Africa | 1 |
| Israel | 1 |
| Norway | 1 |
| India | 1 |
| Russia | 1 |
| Italy | 1 |
| Denmark | 1 |
| Australia | 1 |
| Korea (South) | 1 |
| Spain | 1 |
| Mexico | 1 |
Where are Research Centers of OncoTracker Patents Located?
Best OncoTracker Patents
US10126301B2 is the most popular patent in the OncoTracker portfolio. It has received 2 citations.
Below is the list of 10 most cited patents of OncoTracker:
| Publication Number | Citation Count |
| US10126301B2 | 2 |
| US20190107541A1 | 2 |
| US20200326339A1 | 2 |
| US20220000872A1 | 2 |
| KR1020180033232A | 2 |
| US10363260B2 | 1 |
| US20180214553A1 | 1 |
What Percentage of OncoTracker US Patent Applications Were Granted?
OncoTracker (Excluding its subsidiaries) has filed 8 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 100%.
Below are the key stats of OncoTracker patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for OncoTracker?
| Law Firm | Total Applications | Success Rate |
| Cooley Llp | 4 | 100% |
| Stites & Harbison Pllc | 4 | 0% |
List of OncoTracker patents
| OncoTracker Patents | Title |
| US11246876B2 | Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids |
| US10363260B2 | Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids |
| US10126301B2 | Diagnostic, Prognostic, And Monitoring Methods For Multiple Myeloma, Chronic Lymphocytic Leukemia, And B-Cell Non-Hodgkin Lymphoma |
| US11698369B2 | Methods For Monitoring Immune Status Of A Subject |
| US11635435B2 | Diagnostic, Prognostic, And Monitoring Methods For Solid Tumor Cancers |
| US20230233579A1 | Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids |
| US20190107541A1 | Diagnostic, Prognostic, And Monitoring Methods For Multiple Myeloma, Chronic Lymphocytic Leukemia, And B-Cell Non-Hodgkin Lymphoma |
| US20200326339A1 | Improved Methods For Monitoring Immune Status Of A Subject |
| US20220000872A1 | Method Of Enhancing Immune-Based Therapy |
| EP3402515B8 | Improved Methods For Monitoring Immune Status Of A Subject |
| EP3662909A1 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| EP3873478A4 | Method Of Enhancing Immune-Based Therapy |
| EP4079320A1 | Improved Methods For Monitoring Immune Status Of A Subject |
| CA2992557A1 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| JP7178902B2 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| JP2021167339A | Gamma Secretase Modulators For Treatment Of Immune System Dysfunction |
| IT202100092552T2 | Improved Methods For Monitoring A Subject’S Immune Status |
| DK3402515T3 | Improved Methods For Monitoring The Immune Status Of An Individual |
| ES2898329T3 | Improved Methods For Monitoring The Immune Status Of A Subject |
| RU2748655C2 | Gamma-Secretase Inhibitors For Treatment Of Immune System Dysfunction |
| NO3402515B1 | Improved Methods For Monitoring Immune Status Of A Subject |
| HK40031928A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| SG10201913841SA | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| HK1255694A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| PH12018500187A1 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| KR1020180033232A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| ZA201800917A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| HK40007456A1 | Improved Methods For Monitoring Immune Status Of A Subject |
| MX2018000999A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction. |
| MYPI2018000083A0 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| SA518390791A | Gamma Secretase Levels To Treat Immune System Dysfunction |
| HK40082699A | Improved Methods For Monitoring Immune Status Of A Subject |
| US20180214553A1 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| EP3324965A4 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| WO2020092792A3 | Method Of Enhancing Immune-Based Therapy |
| AU2016297793A1 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| IL256903A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| IN201817005810A | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| ID201807955A | Gamma Secretase Modulations For The Treatment Of Immunity System Disfusion |
| SG11201800566YA | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
| BR112018001480A2 | Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction |
What are OncoTracker key innovation segments?
What Technologies are Covered by OncoTracker?
The chart below distributes patents filed by OncoTracker